PTPRC and neoplasm: FMD changes tumor immune microenvironment by increasing CD45+ cells in tumor cells, as well as CD8+ T cells in both tumor cells and PBMCs, indicating the increased immune cell infiltration and the cancer-fighting ability of FMD.